229 related articles for article (PubMed ID: 22520951)
21. The polycomb group protein enhancer of zeste 2 is a novel therapeutic target for cervical cancer.
Ding M; Zhang H; Li Z; Wang C; Chen J; Shi L; Xu D; Gao Y
Clin Exp Pharmacol Physiol; 2015 May; 42(5):458-64. PubMed ID: 25739318
[TBL] [Abstract][Full Text] [Related]
22. Enhancer of zeste homologue 2 (EZH2) down-regulates RUNX3 by increasing histone H3 methylation.
Fujii S; Ito K; Ito Y; Ochiai A
J Biol Chem; 2008 Jun; 283(25):17324-32. PubMed ID: 18430739
[TBL] [Abstract][Full Text] [Related]
23. Quantitative analysis of EZH2 expression and its correlations with lung cancer patients' clinical pathological characteristics.
Wan L; Li X; Shen H; Bai X
Clin Transl Oncol; 2013 Feb; 15(2):132-8. PubMed ID: 22855181
[TBL] [Abstract][Full Text] [Related]
24. EZH2 is a sensitive marker of malignancy in salivary gland tumors.
Hajósi-Kalcakosz S; Vincze E; Dezső K; Paku S; Rókusz A; Sápi Z; Tóth E; Nagy P
Diagn Pathol; 2015 Sep; 10():163. PubMed ID: 26377323
[TBL] [Abstract][Full Text] [Related]
25. EZH2 promotes gastric cancer cells proliferation by repressing p21 expression.
Xu J; Wang Z; Lu W; Jiang H; Lu J; Qiu J; Ye G
Pathol Res Pract; 2019 Jun; 215(6):152374. PubMed ID: 30952377
[TBL] [Abstract][Full Text] [Related]
26. Poorly differentiated synovial sarcoma is associated with high expression of enhancer of zeste homologue 2 (EZH2).
Changchien YC; Tátrai P; Papp G; Sápi J; Fónyad L; Szendrői M; Pápai Z; Sápi Z
J Transl Med; 2012 Oct; 10():216. PubMed ID: 23110793
[TBL] [Abstract][Full Text] [Related]
27. Expression profile of the polycomb group protein enhancer of Zeste homologue 2 and its prognostic relevance in renal cell carcinoma.
Hinz S; Weikert S; Magheli A; Hoffmann M; Engers R; Miller K; Kempkensteffen C
J Urol; 2009 Dec; 182(6):2920-5. PubMed ID: 19846140
[TBL] [Abstract][Full Text] [Related]
28. High expression of trimethylated histone H3 at lysine 27 predicts better prognosis in non-small cell lung cancer.
Chen X; Song N; Matsumoto K; Nanashima A; Nagayasu T; Hayashi T; Ying M; Endo D; Wu Z; Koji T
Int J Oncol; 2013 Nov; 43(5):1467-80. PubMed ID: 23969945
[TBL] [Abstract][Full Text] [Related]
29. Polycomb group protein EZH2 is frequently expressed in inflammatory breast cancer and is predictive of worse clinical outcome.
Gong Y; Huo L; Liu P; Sneige N; Sun X; Ueno NT; Lucci A; Buchholz TA; Valero V; Cristofanilli M
Cancer; 2011 Dec; 117(24):5476-84. PubMed ID: 21713757
[TBL] [Abstract][Full Text] [Related]
30. Distinct expression of polycomb group proteins EZH2 and BMI1 in hepatocellular carcinoma.
Yonemitsu Y; Imazeki F; Chiba T; Fukai K; Nagai Y; Miyagi S; Arai M; Aoki R; Miyazaki M; Nakatani Y; Iwama A; Yokosuka O
Hum Pathol; 2009 Sep; 40(9):1304-11. PubMed ID: 19386347
[TBL] [Abstract][Full Text] [Related]
31. Clinical and prognostic relevance of EZH2 in breast cancer: A meta-analysis.
Wang X; Hu B; Shen H; Zhou H; Xue X; Chen Y; Chen S; Han Y; Yuan B; Zhao H; Zhi Q; Kuang Y
Biomed Pharmacother; 2015 Oct; 75():218-25. PubMed ID: 26271144
[TBL] [Abstract][Full Text] [Related]
32. Overexpression of enhancer of zeste homolog 2 and MUC1 may be related to malignant behaviour in intraductal papillary neoplasm of the bile duct.
Sasaki M; Matsubara T; Yoneda N; Nomoto K; Tsuneyama K; Sato Y; Nakanuma Y
Histopathology; 2013 Feb; 62(3):446-57. PubMed ID: 23163606
[TBL] [Abstract][Full Text] [Related]
33. Implications of enhancer of zeste homologue 2 expression in pancreatic ductal adenocarcinoma.
Toll AD; Dasgupta A; Potoczek M; Yeo CJ; Kleer CG; Brody JR; Witkiewicz AK
Hum Pathol; 2010 Sep; 41(9):1205-9. PubMed ID: 20573371
[TBL] [Abstract][Full Text] [Related]
34. The prognostic role of EZH2 expression in rectal cancer patients treated with neoadjuvant chemoradiotherapy.
Meng X; Huang Z; Wang R; Jiao Y; Li H; Xu X; Feng R; Zhu K; Jiang S; Yan H; Yu J
Radiat Oncol; 2014 Aug; 9():188. PubMed ID: 25159232
[TBL] [Abstract][Full Text] [Related]
35. The gene for polycomb group protein enhancer of zeste homolog 2 (EZH2) is amplified in late-stage prostate cancer.
Saramäki OR; Tammela TL; Martikainen PM; Vessella RL; Visakorpi T
Genes Chromosomes Cancer; 2006 Jul; 45(7):639-45. PubMed ID: 16575874
[TBL] [Abstract][Full Text] [Related]
36. Histopathological variables and biomarkers enhancer of zeste homologue 2, Ki-67 and minichromosome maintenance protein 7 as prognosticators in primarily endocrine-treated prostate cancer.
Tolonen TT; Tammela TL; Kujala PM; Tuominen VJ; Isola JJ; Visakorpi T
BJU Int; 2011 Nov; 108(9):1430-8. PubMed ID: 21592298
[TBL] [Abstract][Full Text] [Related]
37. Expression of B-cell-specific Moloney murine leukemia virus integration site 1 mRNA and protein in gastric cancer.
Liu PW; Lin Y; Chen XY
J Dig Dis; 2014 Apr; 15(4):166-73. PubMed ID: 24393364
[TBL] [Abstract][Full Text] [Related]
38. EZH2 expression is a prognostic factor in childhood intracranial ependymoma: a Canadian Pediatric Brain Tumor Consortium study.
Li AM; Dunham C; Tabori U; Carret AS; McNeely PD; Johnston D; Lafay-Cousin L; Wilson B; Eisenstat DD; Jabado N; Zelcer S; Silva M; Scheinemann K; Fryer C; Hendson G; Fotovati A; Hawkins C; Yip S; Dunn SE; Hukin J
Cancer; 2015 May; 121(9):1499-507. PubMed ID: 25586788
[TBL] [Abstract][Full Text] [Related]
39. Prognostic impact of the cancer stem cell related markers ALDH1 and EZH2 in triple negative and basal-like breast cancers.
De Brot M; Rocha RM; Soares FA; Gobbi H
Pathology; 2012 Jun; 44(4):303-12. PubMed ID: 22544210
[TBL] [Abstract][Full Text] [Related]
40. Global histone modification of H3K27 correlates with the outcomes in patients with metachronous liver metastasis of colorectal cancer.
Tamagawa H; Oshima T; Numata M; Yamamoto N; Shiozawa M; Morinaga S; Nakamura Y; Yoshihara M; Sakuma Y; Kameda Y; Akaike M; Yukawa N; Rino Y; Masuda M; Miyagi Y
Eur J Surg Oncol; 2013 Jun; 39(6):655-61. PubMed ID: 23523318
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
